幽门螺杆菌(Helicobacter pylori)是一种致病菌,在全球的感染率超过了50%,是多种胃肠道疾病甚至是胃癌的主要致病因素。共聚集作用存在于菌与菌之间,已经逐渐开始应用在治疗H.pylori感染领域。利用共聚集作用来缓解H.pylori感染的研究主要集中在罗伊氏乳杆菌DSMZ17648,该文拟探究其他具有H.pylori共聚集能力的乳杆菌缓解H.pylori感染的效果。首先通过体外共聚集实验及人胃腺癌细胞(AGS)黏附实验在25株可食用乳杆菌中筛选出与H.pylori具有强共聚集作用的发酵乳杆菌菌株FBJSYZ21-1,之后对发酵乳杆菌FBJSYZ21-1进行进一步的临床效果评价。临床研究共有37名受试者完成,其中安慰剂组15名,发酵乳杆菌FBJSYZ21-1组22名。受试者每天早晚2次服用菌粉,为期4周。临床结果表明,相较于安慰剂组受试者的14C呼气降低值,发酵乳杆菌FBJSYZ21-1干预后得到了显著提高,达到(263.04±179.36)(P<0.05)。同时,发酵乳杆菌FBJSYZ21-1干预可以减轻受试者胃肠道不良症状,且未发现对受试者基本生理状态产生影响。
Helicobacter pylori is a common pathogen that infects more than half the global population. It is one of the main pathogenic factors for several gastrointestinal diseases such as peptic ulcer disease, non-ulcer dyspepsia and gastric cancer. Co-aggregation exists among bacteria. It has gradually begun to be used in the treatment of H. pylori infection. The use of co-aggregation to alleviate H. pylori infection has mainly focused on the Limosilactobacillus reuteri DSMZ17648 strain. This research was carried out to investigate the effectiveness of another Lactobacillus with H. pylori co-aggregation ability to alleviate H. pylori infection. Lactobacillus strains were screened through coaggregation assay and cell adhesion assay in vitro, and then assessed their clinical efficacy of it. Thirty-seven subjects completed the clinical study, including 15 in the placebo group and 22 in the intervention group. Subjects were given the probiotics twice daily for 4-week. The clinical results showed that the 14C breath reduction value was significantly improved by the Limosilactobacillus fermentum FBJSYZ21-1 intervention (263.04±179.36,P<0.05), compared to the placebo subjects. Meanwhile, the intervention also reduced the gastrointestinal symptoms and did not affect the basic physiological status of the subjects. Therefore, L. fermentum FBJSYZ21-1 intervention may alleviate the infection and the gastrointestinal symptoms H. pylori caused, and not affect the basic physiological status of the patients.
[1] BURKITT M D, DUCKWORTH C A, WILLIAMS J M, et al.Helicobacter pylori-induced gastric pathology:Insights from in vivo and ex vivo models[J].Disease Models & Mechanisms, 2017, 10(2):89-104.
[2] CHOI I J, KIM C G, LEE J Y, et al.Family history of gastric cancer and Helicobacter pylori treatment[J].The New England Journal of Medicine, 2020, 382(5):427-436.
[3] LANAS A, CHAN F K L.Peptic ulcer disease[J].The Lancet, 2017, 390(10094):613-624.
[4] CROWE S E.Helicobacter pylori infection[J].The New England Journal of Medicine, 2019, 380(12):1 158-1 165.
[5] CHOI I J, KOOK M C, KIM Y I, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer[J].The New England Journal of Medicine, 2018, 378(12):1 085-1 095.
[6] SUGANO K, TACK J, KUIPERS E J, et al.Kyoto global consensus report on Helicobacter pylori gastritis[J].Gut, 2015, 64(9):1 353-1 367.
[7] YANG C H, LIANG L P, LV P J, et al.Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication:A randomized double-blind placebo-controlled trial[J].Helicobacter, 2021, 26(6):e12856.
[8] HAGHDOOST M, TAGHIZADEH S, MONTAZER M, et al.Double strain probiotic effect on Helicobacter pylori infection treatment:A double-blinded randomized controlled trial[J].Caspian Journal of Internal Medicine, 2017, 8(3):165-171.
[9] RYAN K A, O’HARA A M, VAN PIJKEREN J P, et al.Lactobacillus salivarius modulates cytokine induction and virulence factor gene expression in Helicobacter pylori[J].Journal of Medical Microbiology, 2009, 58(Pt 8):996-1 005.
[10] SALAS-JARA M J, SANHUEZA E A, RETAMAL-DÍAZ A, et al.Probiotic Lactobacillus fermentum UCO-979C biofilm formation on AGS and Caco-2 cells and Helicobacter pylori inhibition[J].Biofouling, 2016, 32(10):1 245-1 257.
[11] ZHAO K, XIE Q, XU D, et al.Antagonistics of Lactobacillus plantarum ZDY2013 against Helicobacter pylori SS1 and its infection in vitro in human gastric epithelial AGS cells[J].Journal of Bioscience and Bioengineering, 2018, 126(4):458-463.
[12] ASGARI B, KERMANIAN F, HEDAYAT YAGHOOBI M, et al.The anti- Helicobacter pylori effects of Lactobacillus acidophilus, L.plantarum, and L.rhamnosus in stomach tissue of C57BL/6 mice[J].Visceral Medicine, 2020, 36(2):137-143.
[13] SAKAMOTO I, IGARASHI M, KIMURA K, et al.Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans[J].The Journal of Antimicrobial Chemotherapy, 2001, 47(5):709-710.
[14] SUNANLIGANON C, THONG-NGAM D, TUMWASORN S, et al.Lactobacillus plantarum B7 inhibits Helicobacter pylori growth and attenuates gastric inflammation[J].World Journal of Gastroenterology, 2012, 18(20):2 472-2 480.
[15] SGOURAS D, MARAGKOUDAKIS P, PETRAKI K, et al.In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota[J].Applied and Environmental Microbiology, 2004, 70(1):518-526.
[16] HOLZ C, BUSJAHN A, MEHLING H, et al.Significant reduction in Helicobacter pylori load in humans with non-viable Lactobacillus reuteri DSM17648:A pilot study[J].Probiotics and Antimicrobial Proteins, 2015, 7(2):91-100.
[17] MEHLING H, BUSJAHN A.Non-viable Lactobacillus reuteri DSMZ 17648 (PylopassTM) as a new approach to Helicobacter pylori control in humans[J].Nutrients, 2013, 5(8):3 062-3 073.
[18] CHEN M J, CHEN C C, HUANG Y C, et al.The efficacy of Lactobacillus acidophilus and rhamnosus in the reduction of bacterial load of Helicobacter pylori and modification of gut microbiota:A double-blind, placebo-controlled, randomized trial[J].Helicobacter, 2021, 26(6):e12857.
[19] 张美怡. 具有抗幽门螺杆菌感染作用乳杆菌的筛选及其临床效果评价[D].无锡:江南大学, 2020.
ZHANG M Y.Screening and clinical functional evaluation of Lactobacillus strains for their anti-Helicobacter pylori effects[D].Wuxi:Jiangnan University, 2020.
[20] TIAN P J, CHEN Y, ZHU H Y, et al.Bifidobacterium breve CCFM1025 attenuates major depression disorder via regulating gut microbiome and tryptophan metabolism:A randomized clinical trial[J].Brain, Behavior, and Immunity, 2022, 100:233-241.
[21] 宋雨心, 王文骞, 张园, 等.黏附与聚集、抗肿瘤及抗菌特性乳杆菌的筛选[J].中国预防兽医学报, 2018, 40(11):986-991.
SONG Y X, WANG W Q, ZHANG Y, et al.Screening of the probiotics with adhesion and aggregation, anti-tumor and anti-pathogenic bacteria properties[J].Chinese Journal of Preventive Veterinary Medicine, 2018, 40(11):986-991.
[22] 任大勇. 益生乳酸杆菌的黏附及免疫调节作用研究[D].长春:吉林大学, 2013.
REN D Y.Research on adhesion and immunoregulation of probiotic Lactobacillus strains[D].Changchun:Jilin University, 2013.
[23] HU J, TIAN X, WEI T, et al.Anti-Helicobacter pylori activity of a Lactobacillus sp.PW-7 exopolysaccharide[J].Foods (Basel, Switzerland), 2021, 10(10):2453.
[24] 张美怡, 翟齐啸, 赵建新, 等.鼠李糖乳杆菌JS-SZ-2-1抗幽门螺杆菌感染的临床效果评价[J].食品与发酵工业, 2020, 46(23):29-34.
ZHANG M Y, ZHAI Q X, ZHAO J X, et al.Clinical efficacy evaluation of Lactobacillus rhamnosus JS-SZ-2-1 against Helicobacter pylori infection[J].Food and Fermentation Industries, 2020, 46(23):29-34.
[25] DORE M P, BIBBÒ S, PES G M, et al.Role of probiotics in Helicobacter pylori eradication:Lessons from a study of Lactobacillus reuteri strains DSM 17938 and ATCC PTA 6475 (Gastrus®) and a proton-pump inhibitor[J].Canadian Journal of Infectious Diseases and Medical Microbiology, 2019:3409820.
